Ascendis

What Ascendis does

Ascendis Pharma is a pharmaceutical company focused on developing therapies for rare genetic disorders. Its core product, Yuviwel (navepegritide), received FDA approval in March 2026 as the first and only once-weekly therapy for children aged two and older with achondroplasia, a rare genetic disorder causing dwarfism. The approval was supported by data from three randomized clinical trials demonstrating significantly higher annualized growth velocity versus placebo, along with improved lower-limb alignment and body proportionality.

The company's underlying technology is a pharmaceutical drug development platform targeting rare genetic conditions. Yuviwel's differentiated feature is its once-weekly dosing regimen, which is novel for the achondroplasia indication, and the molecule itself is described as having a novel method architecture. The approval also included a Rare Pediatric Disease Priority Review Voucher, which provides strategic optionality for expediting future drug applications.

Ascendis generates revenue through prescription drug sales of Yuviwel, with planned U.S. commercial availability in early Q2 2026. Distribution will be handled through specialty pharmacies and healthcare providers serving pediatric endocrinology specialists and rare disease treatment centers. Pricing has not been publicly disclosed. The customer base is narrowly defined: pediatric patients aged 2+ diagnosed with achondroplasia, a small population within the broader rare disease segment. Note: the firmographic record describes a separate Romanian training/consulting firm also called Ascendis; the substantive analytical data here pertains to Ascendis Pharma.

Name

Ascendis

Website

https://ascendis.ro

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Ascendis Pharma is a pharmaceutical company that developed Yuviwel (navepegritide), an FDA-approved once-weekly therapy for children aged 2+ with achondroplasia, a rare genetic dwarfism disorder, with U.S. launch planned for Q2 2026.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Rare disease therapeutics
• Pediatric growth disorders
• Achondroplasia treatment
• Rare genetic disorders
• Specialty pharmaceuticals

Headquarters

HQ city

Bucharest

HQ country

Romania

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical drug sales: Revenue generated from sales of FDA-approved rare disease therapy Yuviwel (navepegritide). The company plans to commercialize the therapy in the U.S. market starting Q2 2026.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Ascendis Pharma is a biopharmaceutical company that develops and commercializes rare disease therapies. Its core product is Yuviwel (navepegritide), a once-weekly injectable therapy approved by the FDA for children aged two and older with achondroplasia, a rare genetic disorder causing dwarfism. The therapy is the first and only FDA-approved once-weekly treatment for this condition.

Product overview

Ascendis is a pharmaceutical company that has developed Yuviwel (navepegritide), a once-weekly injectable therapy for pediatric patients aged two and older with achondroplasia. Yuviwel represents the company's core product offering and is the first and only FDA-approved therapy for this rare genetic form of dwarfism.

Differentiator

Problem solved

Functional benefit

Products and services

• Yuviwel (navepegritide) A once-weekly injectable therapy for children aged two and older with achondroplasia, a rare genetic disorder causing dwarfism. It is the first and only FDA-approved treatment for this condition, demonstrated to significantly increase annualized growth velocity compared to placebo while improving lower-limb alignment and body proportionality.

Quantifiable outcome

• Significantly higher annualized growth velocity compared to placebo
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• BioMarin Pharmaceutical: BioMarin markets Voxzogo (vosoritide), the first FDA-approved therapy for achondroplasia, making it the only direct head-to-head competitor in Ascendis's core indication.

Others

• Ascendis Pharma A/S: Denmark-based rare-disease endocrine specialist developing TransCon prodrug therapies including TransCon hGH and TransCon PTH; highly relevant as a namesake rare-disease platform peer, though it is unclear whether the two Ascendis entities are affiliated.

Broad incumbents

• Ultragenyx Pharmaceutical: Commercial-stage rare-disease biotech with a diversified portfolio of approved therapies and a development pipeline focused on rare genetic and metabolic disorders, comparable as a rare-disease commercialization specialist.
• Alexion / AstraZeneca Rare Disease: Established rare-disease franchise within AstraZeneca with multiple approved therapies for ultra-rare conditions, comparable as a broad incumbent with proven rare-disease commercial and patient-services infrastructure.
• Vertex Pharmaceuticals: Commercial rare-disease leader with approved therapies for cystic fibrosis and a growing pipeline in rare genetic disorders, providing a benchmark for orphan-drug commercial scaling.
• Regeneron Pharmaceuticals: Large biotech with an approved rare-disease ophthalmology franchise and a pipeline in rare genetic and metabolic conditions, relevant as a broad incumbent with rare-disease commercial reach.
• Pfizer (Rare Disease): Global biopharma with a substantial rare-disease portfolio through internal development and prior acquisitions, providing a likely large-pharma competitor or potential acquirer for late-stage rare-disease assets.

Emerging players

• BridgeBio Pharma: Clinical and commercial-stage rare-disease company developing therapies for genetic conditions, including skeletal and growth disorders, providing a relevant emerging peer for rare-genetic pipeline execution.
• Ionis Pharmaceuticals: RNA-targeted therapeutics company with multiple approved rare-disease products and a deep rare-genetic pipeline, comparable as an emerging player in rare-disease drug development.
• Sarepta Therapeutics: Rare-disease genetic medicines company with multiple approved therapies for Duchenne muscular dystrophy, relevant as a peer navigating the post-approval commercialization of a rare-disease specialty therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ascendis_ro
• Facebookfacebook.com/ascendis.ro
• LinkedInlinkedin.com/company/ascendis

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascendis